AstraZeneca’s GLP-1 obesity pill shows 10.5% average weight loss after six months in Phase 2 trial
read at Endpoints ↗Positive readoutPositive
AstraZeneca reported data from its Phase 2 study of a GLP-1 based oral obesity treatment.
The trial showed participants lost an average of 10.5% of body weight after six months of therapy.
The results place the drug on par with other candidates from Roche, Pfizer and Structure Therapeutics, intensifying competition for the third market‑ready obesity pill.
AstraZeneca views the data as supporting its broader $5 billion franchise strategy in metabolic disease.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “#ADA26: AstraZeneca's GLP-1 pill cuts weight by 10.5% after six months”
read at Endpoints ↗85 words · retrieved Jun 8
comments(0)
5-min edit window · permanent after that